Experimental combo shows promise for Hard-to-Treat melanoma
NCT ID NCT04570332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of two drugs—BO-112, injected directly into tumors, and pembrolizumab, given through a vein—in 42 adults with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to see if the combo could shrink tumors and be safe. Participants had stage III or IV melanoma and had already progressed on anti-PD-1 therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BO-112 (injected into tumors) plus pembrolizumab (given intravenously)
What this could lead to
If successful, this combination could offer a new treatment option for advanced melanoma patients whose cancer stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 42 participants and no comparison group, so results may not apply broadly. The treatment involves injections into tumors and carries risks like injection site reactions and immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
-
Centre Hospitalier Universitaire de Grenoble
Grenoble, France
-
Centre Hospitalier Universitaire de Nantes
Nantes, France
-
Centre Hospitalier Universitaire de Nice
Nice, France
-
Clínica Universidad de Navarra
Pamplona, Spain
-
H. General Universitario de Valencia
Valencia, Spain
-
H. Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
-
H. Universitari Quirón Dexeus
Barcelona, Spain
-
Hopital Lyon Sud
Lyon, France
-
Hospital Clara Campal - HM Sanchinarro
Madrid, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario Virgen Macarena
Seville, Spain
-
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
-
Hôpital Ambroise-Paré
Paris, France
-
Institut Gustave Roussy
Paris, France
-
MD Anderson Cancer Center
Madrid, Spain